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Background: To identify the effect of ulinastatin (UTI) administration on stress-induced
hyperglycemia and acute insulin (INS) resistance experienced by patients undergoing
partial hepatectomy.
Methods: Forty-six patients undergoing partial hepatectomy were assigned randomly to the
control group (group C) or UTI treatment group (group U). Six cases underwent partial hep-
atectomy but were not eligible for inclusion. The patients in group U had an intravenous
infusion of a total amount of 5000 IU/kg UTI before the induction of anesthesia and at the
start of surgery. The patients in group C were given an identical volume of physiological
saline in the same manner. Blood samples for the measurement of interleukin-6, cortisol,
INS, and glucagon were obtained. Fasting plasma glucose concentration was measured
immediately before skin incision (T1), 20 min after the liver lesion was removed (T2), at the
end of surgery (T3), as well as on the first (T4) and secondmornings after partial hepatectomy
(T5). The insulin sensitivity index (ISI) was calculated at these time points.
Results: The fasting plasmaglucose concentration in groupUwas significantly lower than that
in group C at all time points except for T1. In group U, the insulin sensitivity indexwas higher,
and the levels of interleukin-6, cortisol, and INS were lower than that in group C (P < 0.05).
Conclusions: The data suggest that UTI administration improves perioperative hyperglyce-
mia by inhibiting the inflammatory reaction, as well as excessive release of inflammatory
factors, and improves INS resistance.
ª 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction hyperglycemia is the most common pattern of dysglycemia inDysglycemia during the perioperative period refers to any
disorder in the stability of glucose levels in serum. This in-
cludes diabetes-induced hyperglycemia in previously diag-
nosed or undiagnosed patients; impaired glucose tolerance;
impaired fasting glucose; stress-induced hyperglycemia in
nondiabetic patients; and hypoglycemia. It is very common in
patients undergoing major surgical procedures. However,sthesiology, Guangdong
Guangdong Province 5100
(J. Ma).
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).clinical practice.
Considerable attention has been paid to hyperglycemia
because it is an early warning sign of a poor prognosis [1,2].
Several measures have been taken to avoid hypergly-
cemia in patients undergoing major surgery. However, the
treatment strategy of hyperglycemia is controversial. A
moderate target for glycemic control has not been deter-
mined, and the benefits and risks of intense glucose controlGeneral Hospital and Guangdong Academy of Medical Sciences,
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tioned [3,4].
Hyperglycemia refers to excess glucose in the blood, which
means that glucose is not being metabolized appropriately.
Hyperglycemia in major surgery usually involves hyper-
insulinemia (i.e., cells are deconditioned to the INS stimulus
and do not take up glucose verywell). During such a condition,
INS administration is not the best way to regulate the unstable
level of glucose in blood because INS resistance occurs. Recent
studies have indicated that perioperative hyperglycemia is, in
general, related to the following conditions: preoperative
metabolic condition; dysregulation of the neuroendocrine
system; release of cytokines subsequent to the stress
response; acute INS resistance; specific features of the surgical
procedure, and perioperative management [5,6]. Therefore,
theoretically, any intervention that regulates the neuroendo-
crine stress response and release of cytokines perioperatively
can also modulate the consequent dysglycemia and mitigate
perioperative hyperglycemia. Similar effects of propofol or
opioids have been reported [7].
Hepatectomy is very different from other types of surgery.
It involves very complicated occlusion and reopening of ves-
sels, manipulation of the first and second hepatic portal vein,
and the inferior vena cava. These procedures can contribute to
ischemiaereperfusion injury to liver cells and the release of
many inflammatory factors. These factors serve as a strong
stress response that facilitates hyperglycemia during surgery.
Ulinastatin (UTI) is a broad-spectrum protease inhibitor. It
is a type of glycoprotein separated and purified from human
urine. It has been used widely in patients with acute inflam-
matory disorders such as acute pancreatitis, shock, systemic
inflammatory reaction syndrome, and multiple organ
dysfunction syndrome. In vitro experiments have demon-
strated that UTI ameliorates ischemiaereperfusion injury by
inhibiting neutrophil accumulation in the postischemic liver
[8]. Recent in vivo and in vitro studies have also indicated that
UTI administration can inhibit the additional expression of
inflammatory cytokines such as tumor necrosis factor (TNF-
a), interleukin (IL)-2 and IL-8 (which play important parts in
dysglycemia), impairment of the bloodebrain barrier, as
well as postoperative cognitive dysfunction [9e13]. Recent
research has also suggested that UTI could be a useful marker
of chronic inflammatory conditions in patients with type-1 or
type-2 diabetes [14]. However, treatment of perioperative hy-
perglycemia by UTI administration has not been reported.
We hypothesized that UTI could ameliorate perioperative
hyperglycemia. We obtained blood samples through central
venous catheters that had been inserted via the right jugular
vein after general anesthesia (GA) at several fixed time points
or events during and after hepatectomy. Fasting plasma
glucose (FPG), interleukin-6 (IL-6), cortisol (COR), INS, and
glucagon (GLU) were measured in these blood samples. The
insulin sensitivity index (ISI) was calculated to evaluate the
benefit of UTI for controlling perioperative hyperglycemia.2. Materials and methods
The study protocol was approved by the Ethics Committee of
Guangdong General Hospital (Guangdong Academy of MedicalSciences) and registered in the Chinese Clinical Trial
Registry (Registration number ChiCTR-TRC-13003829). Writ-
ten informed consent was obtained from each patient.
Forty-six American Society of Anesthesiologists (ASA) IeII
patients for laparotomy hepatectomy fromOctober 2012eMay
2013 were enrolled. The inclusion criteria were (i) ChildePugh
score10 and (ii) nometastasis to other organs. The exclusion
criteria were (i) abnormal findings on electrocardiography or
chest radiographs; (ii) cardiac or pulmonary insufficiency; (iii)
severe renal dysfunction; (iv) preoperative hemoglobin level
<100 g/L; (vi) allergies; (vii) history of drug abuse; and (viii)
infusion of glucose-containing liquid <8 h before surgery.
Patients who had one of the following severe complications or
events were also excluded as follows: (i) cardiovascular
events; (ii) allergic shock; (iii) reoperation; (iv) hepatic failure;
and (v) postoperative INS therapy. Patients were assigned
randomly (by a computer-derived random number sequence)
to two groups to intravenous infusion of 2500 IU/kg UTI (UTI
treatment group or group U) or saline (control group or group
C) at the beginning of anesthesia and surgery, respectively.
Double-blind processing was carried out. That is, study drugs
were dissolved in 20 mL physiological (0.9%) saline or only
0.9% saline with the same type of syringe, and markers were
prepared according to the randomized groups by a person
who did not take part in sample measurements or post-
operative follow-up. The attending anesthesiologist and data
collector were blinded to the infusion drug.
The general anesthetic method and perioperative man-
agement were standardized. Five-lead electrocardiography,
noninvasive blood pressure, end-tidal PCo2 (EtCO2), heart rate
(HR), and pulse oximetry (SpO2) were recorded. A central
venous catheter was placed in the right internal jugular vein
for continuous monitoring of central venous pressure. An
electroencephalography monitor version 4.3 (Narcotrend; MT
MonitorTechnik GmbH, Bad Bramstedt, Germany) was con-
nected to patients for assessing anesthetic depth. Atropine
(0.01 mg/kg, intravenously) and midazolam (3 mg, intrave-
nously) were administered to all patients 30 min before sur-
gery. GA was induced with 1.0 mg/kg propofol and 4.0e5.5 ng/
mL remifentanil by target-controlled infusion followed by
injection with 0.6 mg/kg cisatracurium to facilitate tracheal
intubation. GA was maintained with target-controlled infu-
sion of remifentanil and sevoflurane inhalation in O2 (50%e
100%), and the depth of anesthesia with the Narcotrend index
at 20e46 (stage D2eE1) wasmaintained. Intermittent positive-
pressure ventilation with an adequate tidal volume to main-
tain an EtCO2 of 36e40 mm Hg was maintained at a fresh gas
flow of 2 L/min. Extra fentanyl and muscle-relaxation agents
were infused intravenous according to need.
On the premise of a stable depth of anesthesia, fluctuation
of mean arterial blood pressure (MAP) <20% or HR <30% to
baseline was treated by adjusting the end-tidal concentration
of sevoflurane and the infusion target of remifentanil or
intravenous fluid speed. As adverse hemodynamic responses
occurred (defined as fluctuation of MAP >20% or HR >30% to
baseline), vasopressors (dopamine, norepinephrine, or glo-
noin) were infused to maintain hemodynamic stability fol-
lowed by procedures to find out the pathogenesis of the events
and initiate therapy. Bradycardia (HR<45 bpm) was treated by
0.01 mg/kg atropine. Hydroxyethyl starch solution (6%) (130/
Table e Demographic data.
Demographic data Group C Group U
Age (y) 51  11 51  10
M/F (n) 15/5 16/4
Weight (kg) 58.5  7.6 59.4  8.1
BMI (kg/m2) 22.9  2.0 23.0  2.2
ChildePugh grade A/B (n) 17/3 17/3
Duration of surgery (min) 200  35 206  27
Blood loss (mL) 425 (200e625) 400 (100e600)
BMI ¼ body mass index.
No statistical significances were observed between the two groups.
Data are the mean  SD, median, and range or number of patients.
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Shanghai, China) were used for fluid therapy, and blood
products were administered if required.
All patients received intravenous analgesia postopera-
tively using a defined strategy. That is, fentanyl (1 mg/
kg) þ flurbiprofen (80 mg) were infused as the first dose as
soon as the skin was sutured. Doses of 18 mg/kg fentanyl,
200 mg flurbiprofen, and 40 mg azasetron were mixed and
diluted with normal saline up to 100 mL. This mixture was
administered at 2 mL/h and maintained for 50 h using a
disposable pump.
To measure levels of FPG, IL-6, COR, INS, and GLU, samples
of venous blood were obtained before skin incision (T1),
20 min after the liver lesion was removed (T2), at the end of
the hepatectomy (T3), as well as on the first (T4) and second
mornings after hepatectomy (T5). Blood samples (5 mL) were
centrifuged at 3000 rpm for 10 min at 4C. Serumwas stored
at 80C. FPG levels were measured immediately using the
ABL800 FLEX blood gas analyzer (Radiometer, Copenhagen,
Denmark); IL-6 levels were measured using an enzyme-linked
immunosorbent assay kit (ExCell Biology, Shanghai, China);
COR, INS, and GLU levels were measured using a radioim-
munoassay kit (Beijing North Institute of Biological Technol-
ogy, Beijing, China). The ISI was calculated according to the
method of Li and Pan [15] using the formula:
ISI ¼ 1=ðFINS FPGÞ
The natural logarithm of the ISI is used for evaluating INS
sensitivity, that is, the smaller the value, the worse the
impairment of INS sensitivity.
Hyperglycemia was defined as an FPG level >10 mmol/L at
any time point. The prevalence of hyperglycemia in the two
groups was calculated.2.1. Statistical analyses
Statistical analyses were carried out using SPSS version 20.0
(SPSS, Chicago, IL). The sample size in this prospective study
was calculated on the basis of our pilot studywith a¼ 0.05 and
b ¼ 0.80: 18 patients were needed in each group. Numerical
data are the mean  standard error of the mean. Categorical
data are presented as the component ratio. Numerical data,
including concentrations of FPG, IL-6, COR, INS, and GLU as
well as the ISI between the two groups, were analyzed using
the Student t-test. Intragroup numerical data were analyzed
using repeatedmeasures analysis of variance. The prevalence
of hyperglycemia between the two groups was analyzed using
the Pearson c2 test. P < 0.05 was considered significant.3. Results
Forty patients out of 46 candidates completed the study. There
were no significant differences in demographic data between
groups (P > 0.05; Table). There were no significant differences
in HR, MAP, EtCO2, SpO2, and Nacotrend index during hepa-
tectomy between the two groups (P > 0.05). No significant
differences in levels of FPG, IL-6, COR, INS, and GLU or the ISI
between groups were found at T1 (P > 0.05).FPG concentration in the two groups showed a similar
trend. However, FPG concentration increased as hepatectomy
proceeded to amaximumat T2eT3 and then declined after the
procedure (P < 0.05). In group U, FPG concentration was
significantly lower at any timepoint exceptT1whencompared
with group C (P < 0.05). FPG concentration (in millimole per
liter) in group U showed a difference of 2.64  0.60 at T2 (95%
confidence interval 1.41e3.86), 2.20  0.47 at T3 (1.26e3.14),
1.83  0.73 at T4 (0.35e3.30), and 1.85  0.43 at T5 (0.98e2.70)
compared with that in group C (FigureA).
To determine acute INS resistance between the two groups,
the ISI was calculated (FigureB). The ISI decreased during and
after hepatectomy compared with its baseline level (T1) in all
groups (P< 0.05), but the extent of the decrease in group Uwas
much lower at T2eT5 comparedwith that in group C (P< 0.05).
The ISI ingroupUshowedadifferenceof1.100.26atT2 (95%
confidence interval0.57 to1.64),0.97 0.28 at T3 (0.40 to
1.54),0.71 0.32 at T4 (0.06 to1.35), and1.40 0.24 at T5
(0.92 to 1.89) compared with that in group C.
To explain the changes in FPG concentration between the
two groups, concentrations of INS and GLU were measured at
identical points. For INS, the concentrations in the patients of
the two groups showed an upward trend during hepatectomy
and reached a peak at T4, then fell dramatically at T5 (P< 0.05;
FigureC). Compared with group C, the concentration of INS
was significantly lower in group U (P < 0.05) at T2eT3 and T5,
whereas the difference in GLU level between the two groups
was not significant at any time point (P > 0.05, FigureD).
To describe the stress and inflammation reactions, levels
of COR and IL-6 were measured between the two groups. The
concentration of COR increased during hepatectomy and fell
after surgery, and the difference between the two groups was
significant (P < 0.05) at T2eT5 (FigureE). The concentration of
IL-6 increased during hepatectomy and reached a peak at T4
(compared with T1, P < 0.05) in the two groups. However,
group U had a lower IL-6 concentration than that in group C
(P < 0.05) at T2eT3 (FigureF).
Group U showed a lower prevalence of hyperglycemia
compared with group C (5% versus 45%, c2 ¼ 8.53, P < 0.01)
when we defined perioperative hyperglycemia to be 10 mmol/
L. The prevalence of postoperative complications (e.g., fever
and poor wound healing) was not significantly different be-
tween the two groups (P > 0.05). The other postoperative
indices (including period of hospitalization, neutrophil num-
ber, and level of aspartate transaminase) were also not
significantly different between the two groups (P > 0.05).
Figure e Effect of UTI on stress hyperglycemia and acute INS resistance. (A) The FPG level in the two groups showed a
similar trend during and after partial hepatectomy. The FPG level was significantly lower in group U compared with that in
group C. (B) UTI treatment ameliorated the impairment of INS sensitivity during and after partial hepatectomy. (C) Effect of
UTI on INS level. (D) The difference in GLU level between groups was not significant at any time point. (E) Effect of UTI on
COR level. (F) Effect of UTI on IL-6 level. T1: before skin incision; T2: 20 min after removal of the liver lesion; T3: end of
surgery, T4: first morning after surgery, and T5: second morning after surgery ※P< 0.05.
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UTI at 300,000 IU per day has been found to be the recom-
mended dose for acute circulatory failure in clinical studies
[16]. Another study in Japan demonstrated that UTI 6000 IU/kg
is the maximum safe dose [17]. In the present study, total
administration of 5000 IU/kg UTI was studied.
We observed that UTI administration clearly attenuated
the severity and duration of perioperative hyperglycemia. The
FPG concentration in group U was lower during and after
hepatectomy than that in group C, andwas then restored to its
preoperative level at the second morning after surgery. A po-
tential mechanism may be the modulation of the stress
response and release of inflammatory cytokines by UTI.
The variation in COR level is closely associated with the
degree of trauma. The present study demonstrated that the
range of increase of the COR level in patients who underwent
UTI treatment during and after hepatectomy was significantly
lower than that in group C. This finding suggested that UTI
could effectively reduce the stress response arising from surgi-
cal trauma. Activation of the hypothalamusepituitaryeadrenal
cortex axis plays a pivotal part in the perioperative stress
response. COR (whose secretion increases on intraoperative
stress) can (together with adrenaline and GLU) trigger hyper-
glycemia by targeting enzyme substrates, taking up gluco-
neogenic precursors in the liver, boosting the mobilization of
glycogen stores, facilitating glucose release in the liver, pro-
moting dysplasia andmobilization of fasting glycogen reserves,
and prompting the liver to release glucose andminimizing entry
of glucose into the liver [6].
To investigate pancreatic endocrine function during the
perioperative period, the INS:GLU ratio was calculated ac-
cording to the groups. In this way, the relationship betweenthe UTI gradient and the pancreatic function could be
assessed. Theoretically, GLU can promote glycogenolysis and
gluconeogenesis under stress, but GLU secretion did not show
obvious changes between groups. This unexpected finding
suggested that GLU did not contribute much to perioperative
hyperglycemia. According to one study, this phenomenon
might be related to reflex inhibition of hyperglycemia against
GLU secretion [18]. INS is the only hormone that can lower
blood glucose levels. INS secretion can be triggered by an
increased concentration of FPG but is not completely parallel
to the FPG level, and other factors such as INS resistance are
also involved [3]. In the present study, INS secretion in the two
groups peaked on the first day after hepatectomy. However,
the INS concentration in group U was significantly lower than
that in group C, which was due to differences in the FPG level
and INS resistance (i.e., the change in the ISI) between groups.
In the present study, UTI was administered twice sepa-
rately to ensure an effective plasma concentration throughout
surgery as far as possible because of its short half-life in vivo.
With the plasma concentration decreasing after surgery,
blood-glucose regulation by UTI is usually considered to be
restricted to the intraoperative period rather than the post-
operative period. However, the postoperative differences in
FPG levels in the two groups could have been attributable to
the beneficial amelioration of INS resistance, which might
contribute to a reduction in surgical trauma by UTI.
Considering the fact that it is most noticeable on the first
postoperative day [3], INS resistance has a critical role in
sustaining postoperative hyperglycemia, along with ceased
surgical stimulation and recovered hormone levels related to
stress after surgery. Hyperinsulinemic euglycemic clamp
technique (HECT) is considered as the most authoritative
method to evaluate INS sensitivity. However, HECT is an
expensive and time-consuming process, which constrains its
j o u r n a l o f s u r g i c a l r e s e a r c h 1 9 3 ( 2 0 1 5 ) 2 2 3e2 2 8 227application. Li and Pan [15] reported a simple index, which is
fit for the evaluation of the ISI in Chinese population because
of its significant correlation with the ISI determined by HECT.
In the present study, intraoperative and postoperative ISI
values calculated by the way of Li and Pan were higher in
group U than those in group C, which suggested that the
impairment in INS sensitivity was ameliorated by UTI. To
investigate the relationship between inflammatory factors
and INS resistance, plasma levels of IL-6 were measured.
However, as a cytokine with multiple functions, the TNF-a
concentration is influenced by several factors. Most of our
patients had malignant hepatic tumors, and TNF-a levels in
such patients are higher than those of healthy subjects [19].
For this reason, the TNF-a concentration was not studied.
It has been reported that UTI can restrain the excessive
release of inflammatory factors such as TNF-a and IL-6 [11,12].
We also found that the IL-6 concentration in group U was
significantly lower than that in group C except for the second
morning after surgery. TNF-a and IL-6 are the main inflam-
matory factors released after tissue damage and are involved
in the development of INS resistance [3]. TNF-a and IL-6 have
been shown to induce serine phosphorylation of INS receptor
substrate-1, which inhibits the normal tyrosine phosphory-
lation of receptor substrate-1, by which cellular signal trans-
mission is suppressed. Furthermore, TNF-a and IL-6 can
enhance lipolysis to increase the amount of free fatty acids
and inhibit glucose transporters [20]. Ultimately, INS resis-
tance occurs.
As mentioned previously, a moderate target for glycemic
control has not been determined. Some authors have sug-
gested that it would be prudent to maintain glucose levels
<10 mmol/L in the perioperative period until further (more
specific) data are accumulated [3]. Several investigators have
defined conventional control target glucose levels during the
perioperative period to be 10 mmol/L [21,22]. In the present
study, hyperglycemia was defined as FPG level >10 mmol/L at
any time point. The prevalence of hyperglycemia was clearly
lower in group U compared with that in group C, which sug-
gested that UTI could reduce the demand for glucose control
by INS. At the same time, no case of low blood glucose was
observed in any patient. With the decreasing demand of
glucose control, the risk of hypoglycemia and necessity of
frequent monitoring of blood glucose also decreased.
This study has some limitations. Only one dose of UTI was
administered intraoperatively. The question of whether UTI
has a dose-dependent effect on perioperative hyperglycemia
is beyond the scope of the present study. Also, because of
objective condition restrictions, there were unparalleled in-
terferences of blood loss and different surgeons in each
patient.5. Conclusions
In conclusion, the present study suggested that UTI admin-
istration improves perioperative hyperglycemia by inhibiting
the inflammatory reaction as well as excessive release of in-
flammatory factors and improves INS resistance. Further
clinical studies examining various doses and prolongation of
UTI for perioperative hyperglycemia are warranted.Acknowledgment
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